Ardelyx presents real-world tenapanor effectiveness analysis in dialysis patients at ASN Kidney Week 2026

ARDX•2026-10-05

Ardelyx said research on tenapanor use and hyperphosphatemia management in dialysis patients is scheduled for presentation at ASN Kidney Week 2026 in Denver.

1. Research presentations

Ardelyx flagged research on real-world tenapanor use alongside phosphate binders, patient-reported treatment challenges, and long-term hyperphosphatemia exposure in dialysis patients for presentation at ASN Kidney Week 2026 in Denver.

2. XPHOZAH session

An exhibitor session will cover XPHOZAH’s mechanism, safety, and add-on use for patients who do not reach guideline phosphorus targets on binders.

Ardelyx presents real-world tenapanor effectiveness analysis in dialysis patients at ASN Kidney Week 2026

1. Research presentations

2. XPHOZAH session

Related News

Nutrien to shut Trinidad Nitrogen operations amid gas supply constraints

Arm sets second-quarter fiscal 2027 earnings release and webcast call

Fortitude Gold declares $0.01 monthly dividend for October 2026

LPL Financial adds Praxis Financial Partners to platform with $1.1 billion in assets

Ball Corp: UBS cuts target price to $63 from $66